Sanofi Launches Hostile $18.5 Billion Bid For Genzyme

PARIS (Reuters) - French drugmaker Sanofi-Aventis launched a hostile bid for Genzyme at $69 per share on Monday, taking its $18.5 billion offer direct to shareholders after Genzyme management refused to negotiate.

Sections:  news   business   
RELATED ARTICLES
  • Bayer to pay $1.1B for California firm Conceptus
    Germany drug company Bayer AG says it intends to buy California-based Conceptus to expand its birth control offerings. Bayer said Monday it would launch a pupublicblic offer to pay $31.00 per share for all the stock in Conceptus, Inc. That means Bayer would pay $1.1 billion. More
  • As drug industry’s influence over research grows, so does the potential for bias
    For drugmaker GlaxoSmithKline, the 17-page article in the New England Journal of Medicine represented a coup. The 2006 report described a trial that compared three diabetes drugs and concluded that Avandia, the company’s new drug, performed best. More
  • Netflix moves to block a hostile takeover
    Netflix is moving to protect itself against hostile takeovers, less than a week after activist investor Carl Icahn disclosed a stake of nearly 10 percent in the online video company. Netflix Inc. said Monday that it has adopted a shareholder rights plan, also known as a poison pill. More
  • Drug Makers Stalled in a Cycle of Quality Lapses and Shortages
    ...These recent quality lapses at big drug companies show that contamination and shoddy practices extend well beyond the loosely regulated compounding pharmacies that have attracted attention because of their link to an outbreak of meningitis... [S]everal industry observers and former plant employees said that the recent quality issues were troubling and that manufacturers had been reluctant to fix problems because stopping production was simply too costly in a business where profits were driven by volume. More
  • Exclusive: GSK set for Human Genome takeover
    GlaxoSmithKline is expected to announce a deal to buy Human Genome Sciences for about $2.8 billion as soon as Monday, ending a three-month hostile pursuit of the U.S. biotech company on friendly terms after sweetening its offer. More
BING NEWS:
  • Kratos Defense & Security Solutions, Inc. (KTOS) CEO Eric DeMarco on Q1 2020 Results
    Q1 2020 Earnings Conference Call May 7, 2020 5:00 PM ET Company Participants Marie Mendoza - SVP and General Counsel Eric DeMarco - President and CEO Deanna Lund - EVP and CFO Conference Call ...
    05/7/2020 - 5:13 pm | View Link
  • More

 

Comment On This Story

Welcome to Wopular!

Welcome to Wopular

Wopular is an online newspaper rack, giving you a summary view of the top headlines from the top news sites.

Senh Duong (Founder)
Wopular, MWB, RottenTomatoes

Subscribe to Wopular's RSS Fan Wopular on Facebook Follow Wopular on Twitter Follow Wopular on Google Plus

MoviesWithButter : Our Sister Site

More Business News